© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Pharmaceutical progress often relies on unsung heroes in the lab. Cefoxitin Acid traces back to the relentless efforts of the 20th century, when scientists chased new solutions to penicillin-resistant bacteria. Chemists in the 1970s drew on cephalosporin's core structure, shaping the cepham series through careful structural tweaks. Cefoxitin, built through acylation of 7-aminodeacetoxycephalosporanic acid (7-ADCA), embodies that creativity. The addition of a 7-alpha-methoxy group shifted the game, widening the spectrum against gram-negative and certain anaerobes, making cefoxitin less susceptible to beta-lactamases. The acid form surfaced as both a direct intermediate and a research subject, carving out its role in synthetic chemistry and medicine. Behind every incremental change stood chemists enduring long nights, penning notes by hand, trialing solvents, and watching colors shift in Erlenmeyer flasks, all with the hope of saving lives in intensive care units decades later.
Cefoxitin Acid, or 7-alpha-methoxy-3-carbamoyloxymethyl-3-cephem-4-carboxylic acid, carries heavy weight in the pharmaceutical world. Its role as a necessary intermediate in the production of cefoxitin sodium salt means it anchors supply chains for injectable antibiotics. For years, bulk manufacturers and researchers placed orders for this fine powder whose purity and stability dictate the next step toward an effective antibiotic product. Business leaders and chemists alike learned to recognize its off-white or beige hue and faint odor. Recognizing this substance means respecting all the steps before it—the fermentation, extraction, purification—and knowing the global importance of each carefully handled kilogram.
Cefoxitin Acid appears as a crystalline, off-white powder. Its structure runs deep: a beta-lactam ring fused to a dihydrothiazine core with a 7-alpha-methoxy substitution. The molecule’s carboxylic and carbamoyl groups impact both solubility and reactivity, giving it a modest solubility in water yet better in alkaline solutions. With a molecular weight around 389.4 g/mol, it carries enough heft to stand out in chromatography or mass spectrometry. Under analytical scrutiny, scientists spot peaks near 179–182°C for its melting point, and the pKa values reveal how it behaves in salt- or acid-forming reactions that drive antibiotic synthesis downstream. Its stability drops sharply under acidic or basic stress, underlining how careful storage—avoiding high heat, minimizing moisture—is crucial from lab bench to warehouse.
Pharmacopeia-grade Cefoxitin Acid demands tight specifications. Purity runs above 98%, affirmed by high-performance liquid chromatography. Impurities like cephalosporanic isomers stay under defined limits. Residual solvents, heavy metals, and bacterial endotoxins fall below strict thresholds. Each container wears a label stating batch number, production date, expiry, storage advice (usually between 2–8°C), and a warning that handling should follow standard chemical hygiene. Labels also carry hazard symbols due to potential irritancy or allergenicity, with regulatory numbers for traceability. Manufacturers answer not only to global agencies but also to every hospital pharmacist who knows that a single contaminant can derail an entire batch of lifesaving drug.
Commercial preparation of Cefoxitin Acid rarely takes shortcuts. Chemists start from 7-ADCA, installing the methoxy group at the 7-position using dimethyldioxirane or similar reagents for selective oxidation. Introducing the carbamoyl group requires precise, often moisture-controlled, conditions—commonly urea derivatives in a buffered solution. Isolating and purifying the acid means batch after batch of crystallization, solvent partitioning, and lyophilization. Thin-layer chromatography checks each fraction, confirming identity before pooling the right lots. Each operation brings unique hazards—beta-lactam dusts can trigger allergic reactions—so veteran operators rely on microbiological-grade cleanrooms, glove boxes, and HEPA filtration. The final substance faces battery after battery of quality assurance testing that narrows over months or years through feedback from analysts, regulators, and production engineers who know shortcuts cost more in product recalls than they ever save up front.
The cepham skeleton of Cefoxitin Acid offers rich ground for exploration. Skilled chemists alter substituents at the 3- or 7-positions to yield new analogs with distinct antibacterial profiles; sometimes they swap functional groups to dodge resistance mechanisms. The acid function allows salt formation—for formulation as cefoxitin sodium, for instance—with simple neutralization reactions. Protecting groups sometimes need removal at precise steps, demanding reagents that won’t harm the delicate beta-lactam bond. Such modifications yield patentable new drugs or research probes, but not all work out: a small tweak might mean total loss of activity or throw off pharmacokinetics. Every failed reaction still advances understanding, if not the product pipeline.
Anyone searching for Cefoxitin Acid in scientific papers, catalogs, or regulatory filings will encounter its full chemical name, but also alternate designations. Some know it as 7-Methoxycephalosporanic acid; others refer to it by its CAS number, or by short-hand product codes internal to particular suppliers. Pharmacopoeia monographs and patent applications often list these synonyms for transparency. Among procurement officers and researchers, precise naming avoids costly shipping errors or regulatory holdups. Trade names abound, but each signifies the same promise—a reliable step in the chain from lab to patient.
Handling beta-lactam intermediates means dealing with powders that cause allergies, sensitization, and respiratory irritation. Those who weigh, measure, or transport Cefoxitin Acid wear PPE: nitrile gloves, disposable lab coats, and sometimes full-face respirators. All manipulations take place within fume hoods or gloveboxes. Spills get absorbed with inert material and disposed of according to hazardous waste codes, not simply tossed in trash. Storage in tight, light-resistant, and cool conditions helps preserve quality and prevent hydrolysis. Documentation spans everything from Material Safety Data Sheets to incident logs, with safety officers checking compliance on a regular basis. A culture of safety saves fingers and careers—not a single operator forgets that fact twice.
Pharmaceutical manufacturers, research labs, and regulatory bodies all have reasons to work with Cefoxitin Acid. Its main application sits in the antibiotic supply chain, where it acts as a precursor to cefoxitin sodium for injectable solutions. That product remains a staple for treating pelvic infections, intra-abdominal sepsis, and as prophylaxis in surgeries where anaerobic bacteria pose a threat. Beyond manufacturing, chemists use Cefoxitin Acid to study resistance, structure-function relationships, and to synthesize new derivatives for preclinical testing. Academic research into new antibiotics often turns on access to pure intermediates like these, bought in milligrams or synthesized by graduate students following yellowing lab protocols from decades past.
R&D teams build on the foundation Cefoxitin Acid provides, searching for next-generation antibiotics with broader spectra, slower resistance development, or improved dosing profiles. Medicinal chemists take this core and draft modifications, relying on data from clinical microbiologists who document rising carbapenemase- or ESBL-producing bacteria in every continent. Synergy and antagonism studies, crystallography of enzyme-inhibitor complexes, and in vivo toxicity checks all start here. Success stories shape not only profits but global health metrics, particularly as drug-resistant bacteria exact rising costs in both developed and developing nations. Investments in synthetic routes, greener chemistry, or process intensification come from both top-down executive mandates and grassroots innovation from bench scientists who know that a single step’s improvement can accelerate discovery across multiple drug classes.
Toxicologists never assume a substance is safe just because it appears in pharmaceuticals. Cefoxitin Acid undergoes in vitro assays on mammalian cell lines and is vetted for mutagenicity, teratogenicity, and dermal sensitivity. Any impurities, even below 0.5%, get run through additional tests, especially since cephalosporin intermediates can trigger allergies or even anaphylaxis in those with penicillin sensitivity. Residual solvents and heavy metals—traces left from upstream or downstream processing—require regular surveillance. Reproductive toxicity, chronic exposure, and cumulative organ loading receive scrutiny from both internal scientists and external regulators. Transparency matters more than ever—most people living with conditions that require antibiotics don’t realize how much work goes into confirming that every liter, vial, or powder sachet meets those unforgiving global standards.
Cefoxitin Acid signals both challenge and promise for those shaping the next century of antibiotics. Threats from antibiotic resistance make research at every stage, from raw material to final injection, more vital than ever. New process chemistry—continuous flow, enzymatic synthesis, or biotransformations—could boost efficiency, yield, and environmental footprint. Tightening regulatory demands and worldwide efforts to secure supply chains mean synthetic routes must get more robust. The hope is that new derivatives or hybrids keep outpacing emerging resistance and reach underserved populations that need fast, reliable access to antibiotics. Every time a child recovers from a severe infection, or a surgery goes complication-free, the work behind Cefoxitin Acid proves its worth. The future belongs to persistent, detail-oriented chemistry combined with informed public health strategy.
Many folks see antibiotics as a modern miracle, but drugs don’t just show up out of thin air. The story often begins with a single, crucial building block. Cefoxitin acid sits right in the middle of this process. Researchers and pharmaceutical makers rely on it to make cefoxitin, a powerful antibiotic used in hospitals to battle serious infections. Its purpose stretches beyond mere chemistry class usage—it’s a key ingredient in keeping bacterial threats under control, especially those that throw ordinary antibiotics for a loop.
Bacterial resistance grows as more people rely on antibiotics. Doctors used to count on ampicillin or penicillin for days when bugs popped up. Now, stubborn strains like methicillin-resistant Staphylococcus aureus (MRSA) show up all over the world. Cefoxitin stands apart because it can handle some of these harder-to-treat bacteria. Cefoxitin acid is the starting point. Without it, manufacturers would run into trouble trying to produce enough cefoxitin for hospitals and clinics.
The process also uses hard science. To make cefoxitin, manufacturers need to start with premium-quality cefoxitin acid. This substance gets churned into its finished form using a mix of laboratory skill and strict quality rules. If the raw material isn’t pure or consistent, patients looking for help might get less than they bargained for.
I remember touring a pharmaceutical plant as a student, seeing workers in full gear handling chemical batches. They watched each step like hawks, knowing a single mistake could mess up an entire batch of medicine. That attention to detail starts with basic ingredients like cefoxitin acid. Without crews bringing their best to this early stage, the system falls apart long before doctors write a prescription.
The journey from chemical to lifesaving drug depends on strict oversight and reliable science. Hospitals order antibiotics expecting each dose to be safe and ready to fight infection. If factories anywhere along the chain cut corners with cefoxitin acid, it risks patient safety. Real-world cases prove why this matters: Substandard antibiotics in some countries fuel resistance, put patients in danger, and spark international concern when bacteria refuse to go quietly.
Manufacturers, regulators, and lab scientists carry a big responsibility. They double-check batches, chase the highest standards, and listen when new threats appear. The World Health Organization issues warnings when low-quality antibiotics circulate, and agencies like the FDA have strict rules for how starting materials like cefoxitin acid must be made and tested. Their goal isn’t red tape—it’s public safety. Everyone depends on responsible sourcing.
Stronger oversight, clearer supply chains, and shared data could lift the game worldwide. No small rural hospital or bustling city ER should end up with substandard medication because someone, somewhere, skimped on quality. My own experience as a patient taught me how invisible most of this effort stays until you really need help. Better transparency would point out where fixes are needed, so the whole system stays honest and effective.
Cefoxitin Acid isn’t just a line on an antibiotic chart—it’s a trusted solution in the fight against tough infections. Doctors and nurses see complicated, fast-moving cases every shift. Cefoxitin works best when given through intravenous (IV) infusion or injection, mostly because it gets straight to the infection faster than tablets ever could. Every nurse knows: IV routes mean precision. The medication doesn’t get stuck in the digestive tract, and absorption isn’t left to chance.
One dose of Cefoxitin Acid usually mixes with saline, often about 100 ml, and travels through a drip over 30 minutes. This method controls how quickly the drug enters the system and helps patients handle it better—even the ones with sensitive stomachs or those prone to side effects. The time matters. Fast runs can mean more risk of reactions or miss out on optimal kill times for bacteria. Slow and steady is the mantra in many infusion rooms.
Treating stubborn infections—think: appendicitis, gynecological infections, or peri-operative prophylaxis—often leads to the same crossroads. Should you push the dose, dilute it further, or try to shorten the administration time for a busy ER? In practice, skipping steps or cutting corners prolongs recovery and contributes to antibiotic resistance, a real headache for anyone working in infectious diseases. I’ve watched patients bounce back faster not just from the drug, but from the careful timing and monitoring during administration.
Nurses double-check for allergies and kidney function before Cefoxitin Acid enters the line. Renal health drives dose adjustments. No two patients heal the same way, so regular kidney function tests catch red flags before trouble starts. I’ve seen physicians prescribe lower dosages or longer intervals after a patient’s lab work flags renal impairment. Rushing can jeopardize lives; one miscalculation, and a kidney could suffer.
Allergic responses, phlebitis, or superinfections happen if the team isn’t vigilant. It isn’t just about the dose, but how it’s given. Watching for rashes, fever, or pain at the IV site means catching complications early. I remember a case where a patient developed redness near the IV site—quick action meant swapping out the line, not just slapping on a bandage. Getting everyone trained to recognize these reactions speeds up interventions. Cefoxitin Acid works only as well as the eyes monitoring it.
Preparation is another headache sometimes. Cefoxitin Acid comes as a powder, and pharmacy staff must mix it with the right diluent, following aseptic technique. I’ve seen mistakes—a rushed nurse using the wrong solution or not quite mixing all the powder. The drug should look clear, not cloudy. Discard and start over, no questions asked, because guessing the potency isn’t worth the gamble.
Hospitals investing in education keep their teams sharp. Updates about recommended infusion times, new dilution protocols, or latest research cut down on error rates and help patients heal faster. Infection control teams run audits and keep everyone honest. They look at how many patients got the drug, how it was prepared, and whether monitoring met the standards. Listening to feedback from bedside workers improves these protocols in real life.
Cefoxitin Acid isn’t a wonder drug on its own; the way it’s given makes all the difference. Smart, careful administration builds trust—patients feel their care team pays attention to every detail. Hospital rooms turn into healing spaces, not just for fighting infection, but for building faith in medicine done right.
Cefoxitin Acid steps into the scene as a strong antibiotic, often prescribed to fight off bacteria that have grown stubborn against other medicines. Doctors might reach for Cefoxitin when common antibiotics start losing their punch. Still, any effective antibiotic brings a set of possible side effects, and Cefoxitin Acid is no exception. No one likes to experience side effects, but knowing what could arise prepares people and their families.
People taking Cefoxitin Acid often mention stomach problems such as nausea, bloating, or diarrhea. These side effects can make it hard to keep up nutrition and daily routines. I remember working in a hospital and seeing patients return to the nurse’s station, looking a little paler than usual, asking if their appetite drop was something to worry about. Sometimes, folks develop a mild rash, an itch, or swelling where the injection went in. These reactions are the body’s way of telling us it doesn't like something, even if the purpose is to cure an infection.
While mild side effects pass, life-threatening allergies don’t give warnings. An allergic reaction to Cefoxitin Acid can cause swelling in the throat or mouth, trouble breathing, and hives. These situations move fast and need urgent help. Patients with a history of penicillin or other beta-lactam allergies should speak up right from the beginning. Documented cases in clinical journals show that while uncommon, such severe reactions to antibiotics have happened, so both patient and provider need to stay alert.
Broad antibiotics like Cefoxitin Acid clear out many types of bacteria, not just the bad ones. This disruption sometimes lets harmful bacteria such as Clostridioides difficile grow in the gut, causing watery diarrhea and cramps. Hospitals have seen outbreaks tied to antibiotic use, and the CDC tracks these cases closely. From what I’ve seen on the wards, doctors encourage reporting loose stools, especially if blood or fever shows up.
Any antibiotic passing through the body relies on the liver and kidneys. Cefoxitin Acid can push these organs a bit harder, causing elevated lab values like AST, ALT, or creatinine. People with weak kidneys might need adjusted doses. I remember pharmacy rounds where dosing discussions focused on recent lab results, aiming to protect the organs while fighting the infection. Some rare cases include yellowing eyes or skin, which signals jaundice, and those need quick tests.
Receiving Cefoxitin Acid by IV or injection often leaves the spot sore or swollen. Sometimes, there’s more intense pain or swelling, and redness may spread. At clinics, nurses regularly rotate injection points and check for any reactions to prevent bigger issues, such as vein inflammation.
Measuring kidney and liver numbers before starting Cefoxitin Acid helps catch risk early. Sharing any allergies or past reactions with your doctor can steer you toward safer options. Hospitals track side effect rates and use guidelines to cut down on repeat problems.
Taking antibiotics like Cefoxitin Acid only when needed and finishing the full course helps cut down not just personal risk, but also wider problems like antibiotic resistance. Patients benefit when providers explain what side effects may show up and what to watch for at home, creating a partnership that keeps treatment effective and safe.
Cefoxitin, a second-generation cephalosporin antibiotic, holds a clear role in tackling many bacterial infections. From skin infections to pelvic inflammatory disease, doctors reach for it because it fights a stubborn bunch of bacteria and helps patients bounce back quickly. Still, like any antibiotic, it doesn’t exist in a vacuum. Using it safely takes real thought about what else a patient is taking, what health problems they live with, and what signs might warn of trouble ahead.
Cefoxitin doesn’t mess with as many drugs as some antibiotics, but it’s not off the hook. Combining it with certain medicines can set off side effects or cut into the medicine’s power. One area I learned about early in my practice was how cephalosporins, including cefoxitin, raise the risk of kidney injury when teamed up with strong diuretics like furosemide or bumetanide. Both are tough on the kidneys and, together, can get risky, especially for older adults or those already dealing with kidney weakness.
Another real-world issue involves blood thinners like warfarin. Cefoxitin can sometimes tangle with how the body manages vitamin K, which plays a key role in clotting. Sudden changes here can alter INR levels and increase bleeding risk. A careful doctor keeps a close watch on blood tests and looks out for unexpected bruising or nosebleeds in patients on both drugs. Antibiotics, including this one, often stir up gut bacteria, and that ripple can stretch as far as blood thinner control.
Also, the risk of “superinfection” crops up when broad-spectrum antibiotics clear out the body’s natural bacteria. Rare but dangerous, Clostridioides difficile (C. diff) infections can follow. People who take acid-suppressing medicines or recent prolonged antibiotics might face a higher risk. For anyone taking more than a short course, this matters.
Allergies call the shots sometimes. Anyone who’s broken out in hives, struggled to breathe, or landed in the hospital after taking penicillin, cephalexin, or similar antibiotics has to stay away from cefoxitin. Cross-reaction rates can reach up to 10% in those with a true penicillin allergy. Missing this point can bring on life-threatening reactions.
Cefoxitin exits the body through the kidneys, which means kidney patients deserve extra care. Doses usually get cut back, and blood levels sometimes get monitored. People living with severe kidney disease or dialysis shouldn’t get standard doses—the risk of toxic buildup is real and can show up as seizures, confusion, or muscle jerks.
For pregnant and breastfeeding women, cefoxitin sits in a middle ground. It hasn’t shown major risks, but the decision should always come with a talk between doctor and patient, weighing infection risk against potential side effects for mom and baby.
The safest approach to cefoxitin always runs through the patient’s full medication list. Teamwork between pharmacist and doctor goes a long way to finding problems before they start. If a patient is on blood thinners or high-powered diuretics, regular follow-up becomes a must. Catching early signs—like swelling, dark urine, unexpected bruises, or gut trouble—makes all the difference.
One of the best habits is education. Patients should know why they’re taking cefoxitin, what to report, and who to call if things go wrong. Just handing out a prescription isn’t the last step; it’s the start of the most important conversation.
Dosing antibiotics, like Cefoxitin Acid, isn’t just following an instruction on a label. Too much puts organs such as the kidneys at risk. Too little gives bacteria another shot at survival, and sometimes, that misstep means watching someone lose a battle they should have won. In my time talking with infectious disease doctors, the most common regret comes from hesitation or underdosing—bacteria that could have been stamped out, given a second chance.
Most clinical guidelines call for adult Cefoxitin dosing at 1 to 2 grams every 6 to 8 hours through intravenous injection. Children usually need anywhere from 80 to 160 mg per kg of body weight per day, split across equal doses. Dosing changes when renal function isn’t normal, or the infection sits in hard-to-reach tissue. A simple urinary tract infection gets less than a bone infection or peritonitis after surgery.
Every person needs the right dose for what’s growing, how sick they are, and whether their organs can process the drug. In medicine, standard never means “one size fits all.” Real people vary wildly—weight, age, kidney function all matter. Lab results often nudge the dose higher or lower, especially for critically ill or elderly patients. Getting a good urine culture or blood sample before starting treatment helps a lot, because the bug type can make a big difference in how much drug is needed for cure.
It’s tempting to imagine doctors always know the answer off the top of their head. Most check international references before setting a regimen, because the risks tied with antibiotics aren’t just one person’s problem. Resistance grows when antibiotics get misused. In my conversations with hospital pharmacists, the golden rule isn’t perfection; it’s working together, checking charts, and tracking kidney numbers.
Patients with reduced kidney function need extra attention. The body clears out Cefoxitin through the kidneys, so even a small dip in kidney function may require a dose cut in half or even less. Without that adjustment, patients risk developing neurotoxic symptoms or worsening kidney damage. Many hospitals flag these patients’ charts to prevent problems before they start.
Every community faces the challenge of bacteria that seem to laugh at last year’s antibiotics. Cefoxitin works best against certain bacteria, but using it for the wrong infection gives bugs a chance to change and resist our best treatments. This isn’t just a hospital problem—misuse spills into the community. In family discussions, loved ones will sometimes push for antibiotics “just in case.” Without a confirmed need and the proper bacteria, this habit puts everyone at risk.
Health systems need more support for stewardship teams that monitor antibiotic use and teach clinicians about the right choice, right dose, and right duration. Many countries now require hospitals to track which antibiotic gets used and when. My experience working on antibiotic policy reviews involved poring over spreadsheets that tracked usage patterns, uncovering trends that led to routine over- or under-dosing, both with bad outcomes.
Open discussion between prescribers, pharmacists, and nurses goes a long way for safer dosing. Patients can ask questions, carry a list of their medications, and make sure the doctor has the latest kidney function test results. Weight and allergies need regular updates; it’s surprising how often old numbers slip through and cause trouble. In my family, double-checking dose calculations with a pharmacist has prevented mistakes more than once.
| Names | |
| Preferred IUPAC name | (6R,7S)-7-[2-(2-methoxyiminoacetyl)amino-2-thiophen-3-ylacetamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Other names |
Cefoxitin Impurity A Cefoxitinoic acid Cefoxitin Side Chain |
| Pronunciation | /səˈfɒk.sɪ.tɪn ˈæs.ɪd/ |
| Identifiers | |
| CAS Number | 35662-12-3 |
| 3D model (JSmol) | `3Dmol.js?cid=64748` |
| Beilstein Reference | 136115 |
| ChEBI | CHEBI:131722 |
| ChEMBL | CHEMBL1257076 |
| ChemSpider | 59343 |
| DrugBank | DB01435 |
| ECHA InfoCard | ECHA InfoCard: 100.044.301 |
| EC Number | 61312-38-7 |
| Gmelin Reference | 1261303 |
| KEGG | C14424 |
| MeSH | D002446 |
| PubChem CID | 86982 |
| RTECS number | XT5010000 |
| UNII | FWS40FYD3F |
| UN number | UN3248 |
| Properties | |
| Chemical formula | C16H17N3O7S2 |
| Molar mass | 427.374 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.8 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 0.02 |
| Acidity (pKa) | 2.7 |
| Basicity (pKb) | 11.08 |
| Magnetic susceptibility (χ) | Magnetic susceptibility (χ): -72.0 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.62 |
| Dipole moment | 2.4397 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 266.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1073.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -1508 kJ/mol |
| Pharmacology | |
| ATC code | J01DC01 |
| Hazards | |
| Main hazards | Causes eye, skin, and respiratory tract irritation. May cause allergic reactions. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | Precautionary statements of Cefoxitin Acid are: "P261, P264, P271, P272, P273, P280, P302+P352, P305+P351+P338, P308+P313, P333+P313, P337+P313, P362+P364, P501 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | > 224.2 °C |
| Lethal dose or concentration | LD50 intravenous (rat) 2400 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Cefoxitin Acid: "≥10 g/kg (oral, mouse) |
| NIOSH | NA |
| PEL (Permissible) | 10 mg/m3 |
| REL (Recommended) | 1.2-4 g daily |
| Related compounds | |
| Related compounds |
Cefoxitin sodium Cefotaxime Cefuroxime Cefazolin Cephalothin |
